• Ranjan Kumar Dora
• Akankshya Purohit
• Udayanath Ratha

RmlC (dTDP-6-deoxyD-xylo-4-hexulase 3, 5 epimerase) is an enzyme. Its main component to produce L-rhamnosyl through the pathway of L-rhamnosyl biosynthetic. The RmlC enzyme is the highly essential enzyme for Mycobacterium tuberculosis. Which main function is cell wall biosynthesis. If it is absent in then the cell wall of Mycobacterium tuberculosis bacterium then the cell wall is Brust and the bacterium will be died. So, it is a valid target for drug design. In this study is an in-silico method study which is helps to know the Potential inhibitor for RmlC. RmlC enzyme. Present day DOTS therapy uses large numbers of drugs for addressing the Tuberculosis problem. These drugs are still a higher rate of incidence and deaths because of this disease. The Tuberculosis bacterium developed it is resistant power, it is the long treatment courses and emergence of cancer from the current medicine of this disease. So, has choose for the identification and isolation of new drugs against Tuberculosis. There are many pathways for the sake of drug inhibitors. The dTDP-6-deoxyD-xylo-4-hexulase 3, 5 epimerase (RmlC) enzyme is an important component to produce L-rhamnosyl through L-rhamnosyl biosynthetic pathway. The RmlC enzyme is one of the four enzymes in the cascade reaction. For the identification and isolation of a potential drug, five molecules were virtually screened onto the enzyme from the Naturally occurring Plant-based Anti-cancerous Compound -Activity- Target database. From this, the molecule 12- deoxy phorbol 13- (9, 10- methylene) undecanoate or NPACT00038 has been selected as a potential drug for the enzyme and may be used as a drug against tuberculosis. However, wet-lab experiment will complement the result more profoundly.

Tuberculosis, RmlC, Mycobacterium tuberculosis, bacterium

"DRUGS DESIGN FOR TUBERCULOSIS: A REVIEW ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 3, page no.a330-a334, March-2023, Available :http://www.jetir.org/papers/JETIR2303043.pdf

"DRUGS DESIGN FOR TUBERCULOSIS: A REVIEW ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 3, page no. ppa330-a334, March-2023, Available at : http://www.jetir.org/papers/JETIR2303043.pdf